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Background. Hepatitis B vaccination has proven to be very safe and highly effective. This study assessed the proportion of suc-
cessfully vaccinated individuals among cases with acute hepatitis B, the proportion of preventable cases if individuals were vaccinated
as recommended, and the reasons for failures.
Methods. We analyzed data reported to the Italian Surveillance System for Acute Viral Hepatitis from 1993 to 2014.
Results. A total of 362 of 11 311 (3.2%) cases with acute hepatitis B were vaccinated. Of the 277 cases for whom immunization
data were available, 50 (18%) received a complete vaccination course according to the correct schedule and before exposure to hep-
atitis B virus. Molecular characterization of 17 of these cases showed that 6 were infected with S-gene mutants. Among the 10 949
unvaccinated cases, 213 (1.9%) escaped mandatory vaccination and 2821 (25.8%) were not vaccinated despite being at increased risk
of infection. Among the latter, the most common risk factors were cohabitation with hepatitis B surface antigen (HBsAg) carriers,
intravenous drug use, and homosexual/bisexual practices. Thirty-seven percent of the unvaccinated households with HBsAg carriers
were aware of their risk. Lack of trust in the vaccination, negative attitude, and inaccurate beliefs followed by lack of or poor com-
munication and low perceived severity of the disease were the most frequent reasons for vaccine hesitancy.
Conclusions. Development of acute disease in successfully vaccinated individuals is a rare event. Further efforts are needed to
enhance the vaccine coverage rate in individuals at increased risk of infection.
Keywords. HBV; surveillance; hepatitis B vaccination; breakthrough infections; vaccination failure.
Hepatitis B virus (HBV) infection and HBV-related diseases are
a major public health issue worldwide. Currently about 240 mil-
lion people are estimated to be chronically infected with HBV,
and more than 780 000 individuals die each year due to hepati-
tis B complications, including cirrhosis and liver cancer [1].
Vaccination is the most effective and economically favorable
measure to control and prevent hepatitis B on a global scale
[2–4]. Italy is one of the ﬁrst countries in the world to imple-
ment a vaccination policy, starting in 1983 with a program
targeted to individuals at increased risk of infection [5–6].
Vaccination became mandatory in 1991 for all infants and all
12-year-olds. This program also includes the mandatory screen-
ing of pregnant women for hepatitis B surface antigen (HBsAg)
in order to identify babies in need of treatment with hepatitis B
immune globulin and vaccine at birth. The program also in-
cludes recommendations for vaccination of groups at higher
risk of infection. At the end of 2003, those in the ﬁrst infant co-
hort vaccinated in 1991 were age 12 years. Thus, the vaccination
of 12-year-olds was stopped, as all children at that age were cov-
ered, while the vaccination of infants was maintained. Because
of the Italian vaccination delivery system’s effectiveness and
public awareness of the disease, the take-up of vaccination
was rapid and reached a coverage rate of >95% within a few
years [7]. To maintain the highest possible coverage rate and,
in turn, guarantee an effective protection at a social level
through herd immunity, parents/legal guardians who miss vac-
cination are required to have their children vaccinated. Oppo-
nents to vaccination are invited to discuss their objections
with the staff of vaccination centers (medical doctors, trained
nurses) who encourage vaccination for the beneﬁt of both indi-
viduals and the community at large. Noneligible children are
exonerated. Parents/legal guardians who choose to opt out de-
spite having been repeatedly invited are asked to sign a waiver.
As a consequence of this policy, approximately 20 million peo-
ple (34 birth cohorts) have been vaccinated against hepatitis B
with an outstanding record of safety and efﬁcacy. This resulted
in a substantial decrease in the burden of disease, carrier rate,
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and HBV-related morbidity and mortality [8, 9]. Despite this
success, there are still cases of acute hepatitis B that are reported
to the national surveillance system for acute viral hepatitis
(SEIEVA [Sistema Epidemiologico Integrato dell′Epatite Virale
Acuta], Istituto Superiore di Sanità, Rome), even among indi-
viduals who have been vaccinated or who should have been vac-
cinated as they were eligible for vaccination.
Our aim in this study was to assess the proportion of success-
fully vaccinated individuals in cases with acute hepatitis B, the
proportion of cases that could have been avoided if fully and
timely vaccinated, and reasons of failures.
METHODS
National Surveillance System for Acute Viral Hepatitis
SEIEVA is a national passive surveillance system that is a sup-
plement to the Italian Ofﬁcial Surveillance System for Infectious
Diseases. It was implemented in 1984 [10]; over 3 decades,
SEIEVA has included a network of Italian local health units
(LHUs), covering a mean of 60% of the Italian population (ap-
proximately 36 million people). As described by Tosti et al [11]
and according to the ongoing protocol, clinical acute cases are
reported by physicians in charge of the diagnosis to the pertain-
ing LHU. Participation is voluntary. Demographic, clinical, ep-
idemiological, and laboratory data as well as information on risk
factors and hepatitis B vaccination status are collected and
maintained in a dedicated database. Information about vaccina-
tion schedule (timing, number of doses, and type of vaccine ad-
ministered) is further conﬁrmed for each case by reviewing the
vaccination registries of the LHUs. All SEIEVA information can
be found on their website (www.iss.it/seieva/).
Study Design and Population
This was a retrospective descriptive study of acute hepatitis B
cases reported to SEIEVA between 1993 and 2014. Within the
SEIEVA surveillance system, the deﬁnition of an acute hepatitis
B case is based on clinical and serological criteria including
acute symptoms consistent with viral hepatitis, signiﬁcant
(more than 10-fold) increase in serum alanine amino transfer-
ase (ALT), immunoglobulin M anti-HBc antibody positivity.
Cases with a previous hepatitis B vaccination were analyzed
to assess whether they were properly vaccinated. For the pur-
poses of this study, a properly vaccinated case was deﬁned as
a diagnosis of acute hepatitis B (clinical breakthrough) in an in-
dividual who had been previously immunized according to our
nationally recommended schedule of vaccination (3 doses given
at 3, 5, and 11 months of age in infants and at 0, 3, and 6 months
in children and adults) and had symptom onset at least 6
months (maximum incubation period) after completing a full
vaccination course. This deﬁnition of HBV breakthrough does
not take into account whether the vaccine recipient developed a
post-vaccination immune response (anti-HBs antibody ≥10
mIU/mL as measured 1–3 months after administration of the
last dose of the initial series), since post-vaccination testing is
not routinely performed in Italy.
All cases with missing information on hepatitis B vaccination
status were excluded from the analysis. Moreover, unvaccinated
cases were studied to determine whether they belonged to high-
risk groups or to groups for which vaccination is mandatory. To
gather information about missing vaccinations, an ad hoc ques-
tionnaire was administered to households with HBsAg chronic
carriers who were aware of the chronic infectious status of their
relatives and acquired acute disease.
All data were anonymously analyzed in accordance with Ital-
ian privacy legislation.
Virological Testing
Molecular characterization of the speciﬁc viral strain causing
hepatitis was possible in only a few cases. In particular, the am-
pliﬁcation of the S gene of HBV DNA was performed in sera
collected during the course of acute hepatitis B. Then, the
HBV genotypes and the presence of mutations in the “a” deter-
minant, that is, the neutralizing epitope within the major
hydrophilic region of the HBsAg, were determined by direct
sequence analysis [12].
Statistical Analyses
Pearson χ2 test or Fisher exact test, when necessary, were used to
assess differences in discrete characteristics between groups,
Figure 1. Study design. Abbreviations: HBV, hepatitis B virus; SEIEVA, Sistema
Epidemiologico Integrato dell’Epatite Virale Acuta.
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such as vaccinated/unvaccinated cases, geographical areas, and
year of diagnosis. The Kruskal–Wallis test was used to investi-
gate the signiﬁcance of by-group differences in continuous
variables.
P values <.05 were considered statistically signiﬁcant. All stat-
istical procedures were performed using the STATA statistical
package, version 13.1.
RESULTS
As shown in Figure 1, 12 472 cases of acute hepatitis B were re-
ported to SEIEVA between 1993 and 2014. Information on hep-
atitis B vaccination status was available for 11 311 (90.7%) cases,
which were included in the study population. The median age
was 36 years (range, 0–100) and 74.9% were males. During this
period, the median age of individuals with hepatitis B signiﬁ-
cantly rose from 26 years in 1993 to 46 years in 2014 (P < .001).
Within the study population, 362 cases (3.2%) occurred in in-
dividuals who had received at least 1 dose of vaccine. The yearly
percentage of cases in vaccinated individuals did not signiﬁ-
cantly change during the study period. Complete information
on vaccination history (ie, number of doses of vaccine adminis-
tered, time between doses) was available for 277 (76.5%) vacci-
nees. In most of these (n = 227; 81.9%), the vaccination schedule
was not completed properly. Vaccine was administered post-
exposure in 151 cases, with a median time lapse between vacci-
nation and onset of disease of 31 days (range, 5–175). Moreover,
40 individuals were administered an incomplete schedule
(24 received 1 dose, 16 received 2 doses), and 36 individuals
received 3 doses but with an incorrect interval between them
(1 individual received the second dose 25 months after the
ﬁrst dose and 35 individuals had a median span of 19 months
[range, 16–41] between the second and the third doses).
Table 1. Comparison Between Properly Vaccinated Cases and Unvaccinated Cases, by Demographic Characteristics, Risk Factors, Hospitalization Rate,







N = 50 N = 10 949
N % N %
Gender
Male 37 74.0 8176 75.2 ns
Female 13 26.0 2703 24.8
Age (y)
0–14 5 10.0 109 1.0 <.001
15–24 13 26.0 1552 14.3
25–34 13 26.0 3377 31.0
35–54 17 34.0 4217 38.7
≥55 2 4.0 1632 15.0
Risk factorb
Intravenous drug use 10 20.4 1139 10.6 .035
Nosocomial exposurec 8 16.0 1863 17.1 ns
Parenteral exposured 15 30.6 3488 32.1 ns
Dental therapy 16 32.7 3312 30.8 ns
Household Hepatitis B surface antigen + 8 21.6 871 10.4 .026
>2 sexual partner 7 22.6 2190 27.7 ns
Unsafe sexual practicese 7 17.1 2076 20.9 ns
Clinical characteristics and liver function tests
Hospitalization 43 86.0 10 176 93.5 .042
Jaundice 42 84.0 9239 85.2 ns
Aspartate amino transferase: mean (SD) 1060 (812) 1453 (1059) .039
Alanine amino transferase: mean (SD) 1730 (1213) 2357 (1375) .011
Total bilirubin: mean (SD) 8.3 (6.7) 11.9 (11.4) .057
Direct bilirubin: mean (SD) 10.0 (20.0) 9.0 (10.1) ns
International Normalized Ratio: mean (SD) 1.2 (0.1) 1.5 (1.0) ns
Data from SEIEVA (Sistema Epidemiologico Integrato dell′Epatite Virale Acuta) 1993–2014.
Abbreviations: ns, not statistically significant; SD, standard deviation.
a Obtained using Mann–Whitney test for continuous variables and χ2 test (or Fisher exact test) for discrete characteristics.
b Each case may report more than 1 risk factor.
c Hospitalization, hemodialysis, surgical intervention, endoscopy, blood transfusion.
d Piercing, tattooing, acupuncture, manicurist/chiropodist attendance, barber-shop shaving.
e Condom use (occasional/never vs always) during occasional sexual intercourses.
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The remaining 50 (18.1%) individuals (74% males; median age
30 years, range, 2–79 years) developed acute hepatitis B after a
median of 7.5 years (range, 223 days–21.5 years), despite having
been given a full course of vaccination according to the correct
schedule and before exposure to HBV. These cases were uni-
formly distributed throughout the observation period. Table 1
shows a comparison of demographic characteristics, risk fac-
tors, clinical characteristics, and liver function tests between
correctly vaccinated and unvaccinated cases. Vaccinated indi-
viduals were signiﬁcantly younger, less frequently hospitalized,
and had lower levels of ALT and aspartate amino transferase
compared with unvaccinated cases. The percentage of intrave-
nous drug users (IVDUs) and households with HBsAg chronic
carriers was signiﬁcantly higher among vaccinated than among
unvaccinated individuals.
Molecular characterization was performed on sera collected
from 17 of the 50 (34%) individuals who were successfully vac-
cinated and showed that 13 of them were HBV-DNA positive.
Genotype F was found in 5 cases, genotype D in 4 cases, and
genotype A in 2 cases, while genotypes B and E were found
in 1 case each. Sequence analysis of the viral “a” determinant
showed that 7 of these cases were infected with wild-type
HBV, while 6 cases carried S-gene mutations (Table 2). Three
of the 6 cases infected with mutant viruses had cocircu-
lating seroprotective concentrations of anti-HBs antibody
(≥10 mIU/mL).
During the study period, 10 949 cases of acute hepatitis B in
unvaccinated individuals were reported to SEIEVA (Figure 1).
Of these, 213 (1.9%) escaped mandatory vaccination. Their dis-
tribution showed a signiﬁcant geographical gradient, with 1.2%
and 1.7% in northern and central Italy, respectively, compared
with 4.4% in southern Italy (P < .001). A total of 187 (87.8%) of
213 cases escaped mandatory vaccination as adolescents and
26 (12.2%) escaped as infants.
Acute hepatitis B was diagnosed in 2821 (25.8%) cases who
were at increased risk of exposure to HBV and for whom hep-
atitis B vaccination was strongly recommended and offered free
of charge. The trend of these cases showed a signiﬁcant yearly
decrease (150–250 cases/year in 1993–2001 vs 40–60 cases/year in
2010–2014; P < .001). As shown in Figure 2, most of the 2821 cases
that were in high-risk groups were IVDUs (n = 1047; 37.1%), in-
cluding 135 (12.9%) who referred to centers for the treatment of
addictions, 843 (29.9%) households with HBsAg chronic carriers,
and 800 (28.4%) homosexual/bisexual men. Among the house-
holds with HBsAg chronic carriers, 310 (36.8%) were aware of
his/her relative’s infectious status. SEIEVA collected information
about the reasons for missed vaccination from 285 of these 310
(91.9%) cases. As shown in Table 3, the main reasons were lack
of trust in the vaccination, negative attitude, and inaccurate beliefs
(67.7%) followed by lack of or poor communication (10.5%) and
low perceived severity of the disease.
Table 2. Molecular Characteristics of 6 Cases of Acute Hepatitis B in
Individuals Properly Vaccinated and Infected With Mutant Hepatitis B
Viruses
Case Number HBV Genotype Mutation Anti-HBs
1 D G145R ≥10 mIU/mL
2 F T118K ≥10 mIU/mL
3 F T126A ≥10 mIU/mL
4 D Q129H Negative
5 D D144E Negative
6 B T143M Negative
Abbreviation: HBV, hepatitis B virus.
Figure 2. Indication for vaccination in 2821 unvaccinated individuals with acute hepatitis B belonging to high-risk group. Abbreviations: HBsAg, hepatitis B surface antigen;
IVDU, intravenous drug users.
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DISCUSSION
Viral hepatitis B is a vaccine-preventable disease. According to
World Health Organization recommendations, more than 183
countries have implemented hepatitis B vaccination into their na-
tional childhood immunization programs [1]. Evidence shows
that after completing a routine 3-dose schedule of vaccination, se-
roconversion to protective concentrations (≥10 mIU/mL) of anti-
HBs is reached in more than 95% of healthy vaccine recipients,
and that protection lasts more than 15–20 years after vaccination,
with no need for booster doses [13–17].The introduction of hep-
atitis B vaccine led to a global decrease in the incidence of disease,
HBV carrier rate, and HBV-related mortality due to cirrhosis or
hepatocellular carcinoma (HCC). In Taiwan, after the implemen-
tation of universal hepatitis B vaccination in 1984, the HBsAg
seropositive rate in children decreased from 10% to 0.9% in
2012 [18]. Concurrent with this decrease, a signiﬁcant reduction
was observed in the incidence of HCC among children and teen-
agers, indicating that the hepatitis B vaccine was the ﬁrst vaccine
used for a major human cancer [19, 20]. Similar results have been
achieved in other previously hyperendemic locations such as
Alaska, Gambia, China, and South Africa [21–24]. In Italy,
where the vaccination of individuals at increased risk of HBV ex-
posure started in 1983 and universal vaccination started in 1991,
data from SEIEVA show a substantial decline in the overall inci-
dence of acute hepatitis B from 5 per 100 000 inhabitants in 1990
to <0.8 in 2014 [25]. The decrease was even more evident in in-
dividuals aged 15–24 years and in those aged 0–14 years in whom
morbidity rates (per 100 000) decreased, in the same period, from
17 to 0.3 (98% decrease) and from 1 to 0.03 (97% decrease), re-
spectively. Moreover, the prevalence of HBV markers also sub-
stantially decreased in children and young adults after
vaccination [8, 9]. A further beneﬁt, due to the biological depen-
dence of hepatitis delta virus from HBV, was that hepatitis delta
also decreased signiﬁcantly in Italy as a consequence of the imple-
mentation of hepatitis B vaccination [26–28].
Some long-term studies have documented HBV breakthrough,
proven by seroconversion to anti-HBc antibody, while virtually
no clinical disease or carriage has been reported to date [29, 30].
Between 1993 and 2014, 96.8% of the 11 311 cases reported to
SEIEVA and included in this study occurred in unvaccinated
individuals; in the remaining 362 (3.2%) cases, acute disease oc-
curred in those who were administered at least 1 dose of vaccine.
Complete information on vaccination status was collected for
277 of the 362 (75%) vaccinated individuals, showing that
only 50 cases out of 227 (18.1%) had received a full primary
course of vaccination according to the proper schedule and
before exposure to HBV. Recalculation of the 18.1% of the
total 362 cases in vaccinated individuals results in an estimated
66 breakthrough cases (correctly vaccinated before exposure)
reported over a 22-year period to SEIEVA. Considering that
during the period of surveillance, SEIEVA covered a mean of
60% of the entire Italian population (approximately 60 million),
we estimate that 5 vaccination failures could occur in Italy each
year. This clearly indicates that breakthrough infections are rare
in Italy, where approximately 20 million individuals, or one
third of the entire population, have been vaccinated. In this con-
text, the herd immunity that is secondary to the large number
of vaccinated individuals may have played a crucial role in the
control and prevention of hepatitis B.
Correctly vaccinated cases were younger, hospitalized less
frequently, and had lower ALT values than those who were
not vaccinated. This could suggest some effect of vaccination
in slowing the natural course of the disease, but this inter-
pretation needs further conﬁrmation. The most common risk
factors identiﬁed among fully vaccinated individuals included
intravenous drug use and a household contact with an HBsAg
carrier; however, the reason for this association needs to be
further investigated. The molecular characterization of the sam-
ples collected from 13 of the vaccinated individuals with break-
through infection who were HBV-DNA positive showed that 7
of them were infected with HBV wild-type and 6 with S-gene
mutants potentially able to evade the vaccine-induced immuni-
ty. Three of these cases developed acute hepatitis B despite the
presence of protective levels of anti-HBs (≥ 10 mIU/mL). It has
been reported that vaccination based on recombinant HBsAg
from HBV genotypes A and D (the vaccines currently used
worldwide) may be less effective toward genotypes E and
F since they display marked differences from the other geno-
types in the “a” determinant domain toward which neutralizing
(protective) antibodies are largely targeted [31]. The fact that
6 (46.2%) cases of breakthrough infection were caused by
genotype F (n = 5) or genotype E (n = 1), which are both
quite rare in Italy, is intriguing even though is important to
say that in Gambia, where genotype E is predominant [32],
and in Alaska, where genotype F is highly diffused [33], vacci-
nation had great success.
Despite the high coverage rate achieved over time in Italy,
cases of acute hepatitis B continue to be reported among indi-
viduals who should have been vaccinated but were not, includ-
ing a number of cases (213; 1.9%) who escaped mandatory
Table 3. Reasons for Nonvaccination Among Households With Hepatitis





Lack of trust in the vaccination, negative attitude,
and inaccurate beliefs
193 67.7
Lack of or poor communication 30 10.5
Low perceived severity of the disease 25 8.8
Doubts about the vaccine’s efficacy 24 8.4
Fear of side effects 13 4.6
Total 285 100.0
Data from SEIEVA (Sistema Epidemiologico Integrato dell′Epatite Virale Acuta) 1993–2014.
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vaccination. The majority of these (87.8%) were adolescents,
most of whom lived in southern Italy.
In 25.8% of unvaccinated cases, acute hepatitis B was diag-
nosed in individuals at increased risk of exposure to HBV for
whom hepatitis B vaccination is strongly recommended and
offered free of charge. Grouping those who escaped mandatory
vaccination with those who were not vaccinated despite being at
high risk of infection, the disease could have been prevented
in 27.7% (3034 of 10 949) of cases if duly vaccinated. However,
the trend of such cases showed a signiﬁcant yearly decrease
(150–250 cases/year in 1993–2001 vs 40–60 cases/year in
2010–2014; P < .001), attributable to an increase in the propor-
tion of vaccinated individuals and possibly to an increasing
herd immunity effect.
Cohabitation with chronic HBsAg carriers, IVDU, and
homosexual/bisexual practices were the major risk factors asso-
ciated with acute hepatitis B. Here, we report an alarming num-
ber of missed opportunities for immunization in 13% of IVDUs
who were being seen at treatment centers before the onset of
acute hepatitis and in at least 37% of households with HBsAg
carriers who were not vaccinated despite being aware of the
condition of their cohabitant(s). For this latter group, data col-
lected using an ad hoc questionnaire showed that lack of trust in
the vaccination, negative attitude, and inaccurate beliefs
followed by lack of or poor communication and low perceived
severity of the disease were the most frequent reasons for
vaccine hesitancy.
In conclusion, data from this study show that the Italian pro-
gram of vaccination resulted in substantial progress toward the
prevention and control of hepatitis B infection. Cases of acute
hepatitis B reported in successfully vaccinated individuals are
currently infrequent and rarely caused by vaccine-escape S
gene viral mutants. Further efforts to achieve and maintain a
high level of public conﬁdence in the safety and efﬁcacy of hep-
atitis B vaccination are essential to reaching high coverage rates,
especially among individuals at increased risk of HBV infection.
A limitation of this study is that SEIEVA does not collect data
on the follow-up of vaccinated individuals with hepatitis B, thus
missing the opportunity to determine whether, in case of infec-
tion, vaccination can protect against the development of a chron-
ic carrier state. However, since the risk of becoming a chronic
carrier is known to be largely age dependent, with a higher fre-
quency in younger individuals compared with adults [34], the
fact that the median age of our cases increased from 26 years
in 1993 to 46 years in 2014 is reassuring. The vaccine-induced
shifting of infection to those who are older, in fact, favors a reduc-
tion in the rate of infected individuals who can develop a chronic
carrier state. Further studies are needed to better clarify this issue.
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